BioSpace News Archive

PRC, a leader in the healthcare intelligence space, announced today that it will be including CARES™ Connect—an innovative discharge solution designed to improve patient perceptions, increase HCAHPS scores, and reduce hospital readmissions—as part of their exclusive Vizient member offerings.

The global Anti-Infective Ophthalmic market size is estimated to be worth US$ 1468.1 million in 2021 and is forecast to a readjusted size of US$ 1849.8 million by 2030 with a CAGR of 3.3% during the forecast period 2022-2030.

The global Bacillus Coagulans market size is estimated to be worth US$ 85 million in 2021 and is forecast to a readjusted size of US$ 147.6 million by 2028 with a CAGR of 8.1% during the forecast period 2022-2030.

The global Clotrimazole market size is estimated to be worth US$ 5 million in 2021 and is forecast to a readjusted size of US$ 5 million by 2030 with a CAGR of 1.2% during the forecast period 2022-2030.

The global DNA Vaccines market size is estimated to be worth US$ 4642 million in 2021 and is forecast to a readjusted size of US$ 7849.6 million by 2030 with a CAGR of 7.7% during the forecast period 2022-2030.

The global Epidermal Growth Factor (EGF) market size is estimated to be worth US$ 135.6 million in 2021 and is forecast to a readjusted size of US$ 200.8 million by 2030 with a CAGR of 5.7% during the forecast period 2022-2030.

The global Life Science Reagents market size is estimated to be worth US$ 39160 million in 2021 and is forecast to a readjusted size of US$ 67090 million by 2030 with a CAGR of 7.9% during the forecast period 2022-2030.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that The Lancet Gastroenterology and Hepatology has published data from the Phase 1b study of CEND-1.

Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled Medicare Advantage company, will release its second quarter 2022 financial results on Thursday, Aug. 4, 2022, after market close.

Oncocyte Corporation today announced that DetermaIO™, the Company’s proprietary test designed to determine the likelihood of benefit of immune checkpoint inhibitors (ICIs), was featured in a podium presentation at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, held in Barcelona, Spain from 29 June-2 July, 2022.